← ANALYST RATINGS · TIPRANKS
Charles River Labs (CRL): analyst forecast and price target
Analyst consensus
Strong Buy14 Buy2 Hold0 Sell
Ratings of 16 analysts in the last 3 months12-month forecast
Based on 16 price targets given in the last 3 months, the average target is $322, the highest $357, the lowest $219. The average is +7.3% from the last price of $300.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $310 → $345+11.3% | Buy | +14.9% | Reiterated | 16.10.26on TipRanks Oct 17 08:14 | −0.9% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $300 → $340+13.3% | Buy | +13.3% | Assigned | 12.10.26on TipRanks 09:00 | +0.1%next day −0.9% | ↗ |
| Ryan Halsted★★★★★★★★★★#3317 · hits 60% · avg +9.0% | RBC Capital | $322 | Buy | +7.3% | Reiterated | 06.10.26on TipRanks 21:45 | −1.3%next day −0.3% · 5 days +1.5% | ↗ |
| Kevin Caliendo★★★★★★★★★★#2646 · hits 56% · avg +5.6% | UBS | $357 | Buy | +18.9% | Initiated | 30.09.26on TipRanks 05:40 | −0.1%next day −3.0% · 5 days −0.1% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | — | Buy | — | Reiterated | 28.09.26on TipRanks 09:40 | +1.3%next day +0.6% · 5 days +4.3% | ↗ |
| David Windley★★★★★★★★★★#769 · hits 59% · avg +9.3% | Jefferies | $305 → $340+11.5% | Buy | +13.3% | Reiterated | 28.09.26on TipRanks 08:20 | +1.3%next day +0.6% · 5 days +4.3% | ↗ |
| Justin Bowers★★★★★★★★★★#8679 · hits 47% · avg 0.0% | Deutsche Bank | $300 → $320+6.7% | Buy | +6.6% | Assigned | 25.09.26on TipRanks 08:40 | −1.1%next day +1.3% · 5 days −0.7% | ↗ |
| Elizabeth Anderson CFA★★★★★★★★★★#2664 · hits 55% · avg +4.4% | Evercore ISI | $320 → $330+3.1% | Buy | +9.9% | Reiterated | 25.09.26on TipRanks 08:00 | −1.1%next day +1.3% · 5 days −0.7% | ↗ |
| Ann Hynes★★★★★★★★★★#1003 · hits 59% · avg +8.1% | Mizuho Securities | $264 → $295+11.7% | Hold | −1.7% | Reiterated | 25.09.26on TipRanks 07:35 | −1.1%next day +1.3% · 5 days −0.7% | ↗ |
| Eric Coldwell★★★★★★★★★★#1091 · hits 59% · avg +7.7% | Robert W. Baird | $291 → $334+14.8% | Buy | +11.3% | Reiterated | 25.09.26on TipRanks 07:20 | −1.1%next day +1.3% · 5 days −0.7% | ↗ |
| Charles Rhyee★★★★★★★★★★#1937 · hits 54% · avg +5.6% | TD Cowen | $300 → $325+8.3% | Buy | +8.3% | Assigned | 25.09.26on TipRanks Sep 24 19:10 | −1.1%next day +1.3% · 5 days −0.7% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $300 → $330+10.0% | Buy | +9.9% | Reiterated | 24.09.26on TipRanks Sep 25 04:45 | +6.3%next day −1.1% · 5 days −2.2% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $304 → $284−6.6% | Hold | −5.4% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $304 → $287−5.6% | Hold | −4.4% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $308 → $286−7.1% | Hold | −4.7% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $295 → $287−2.7% | Hold | −4.4% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $313 → $301−3.8% | Hold | +0.3% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $287 → $293+2.1% | Hold | −2.4% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| Jared Haase★★★★★★★★★★#1700 · hits 89% · avg +24.8% | William Blair | — | Buy | — | Reiterated | 24.09.26on TipRanks 15:55 | +6.3%next day −1.1% · 5 days −2.2% | ↗ |
| Unknown Analyst | Stephens | $320 | Buy | +6.6% | Initiated | 22.09.26on TipRanks Sep 24 15:55 | +2.2%next day −2.0% · 5 days +5.0% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | $250 → $330+32.0% | Buy | +9.9% | Assigned | 16.09.26on TipRanks Sep 17 08:30 | +0.6%next day +1.9% · 5 days −0.6% | ↗ |
| Michael Luo CFA★★★★★★★★★★#2730 · hits 49% · avg +11.8% | CLSA | $219 | Hold | −27.0% | Downgrade | 20.07.26on TipRanks 05:15 | −1.9%next day −1.0% · 5 days +2.5% | ↗ |
| Patrick B Donnelly★★★★★★★★★★#2106 · hits 54% · avg +6.0% | Citi | $265 | Buy | −11.7% | Reiterated | 08.07.26on TipRanks 06:55 | −1.8%next day +3.5% · 5 days +0.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Charles River Labs
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $313 at a price of $295 (+6.1%); now: $322 at $300 (+7.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 13 | 19 | 19 | 19 | 29 | 29 |
| Hold | 3 | 4 | 5 | 4 | 4 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.97 (from $2.93 to $3.09). Last quarter: $3.02.
Sales
Next quarter’s sales estimate — $960M (from $951M to $984M). Last quarter: $1.0B.
Best top-analyst consensus in the sector · Healthcare
About Charles River Labs
- CEO: Birgit Girshick
- Employees: 19,000
- 251 Ballardvale Street, Wilmington, MA, 01887, US
- www.criver.com
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provide
Data from the stock’s TipRanks forecast page, read 30 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗